|Wilkinson-Berka group. L-R: Mr Jack Jerome, Ms Osanna Wong, Mr |
Saeed Alrashdi, Dr Devy Deliyanti, Professor Jenny Wilkinson-Berka.
Jack, Devy and Jenny are authors on the paper.
Ground-breaking research by Monash University scientists has demonstrated the previously unknown existence of a disease-fighting immune cell in the eye and points to potential novel ways of treating eye disorders in premature babies and diabetic adults.
The scientists, led by Professor Jennifer Wilkinson-Berka in the Central Clinical School’s new Department of Diabetes, were investigating improved ways of treating retinopathy of prematurity (ROP), which occurs in very small, prematurely born babies.
ROP is the main cause of vision loss and blindness in children globally. Current treatment is laser surgery on newborn babies to burn the damaged blood vessels that occur with the disorder, which also damages healthy cells.
|Tregs in the retina|
“People thought you couldn’t actually have Tregs in eye tissue because the eye, like the brain, has a barrier that stopped them from entering. No one had ever described this before,” Professor Wilkinson-Berka said. “I thought there might be a weakness in the barrier.”
The researchers confirmed this using animal models. They then boosted the cells to test whether they could repair damaged blood vessels in the retina and found that ROP was significantly reduced.
Their findings appeared in the journal Nature Communications xxx.
Professor Wilkinson-Berka said improving treatments for babies with ROP was increasingly important as technology improved, saving increasingly small babies. “We’re seeing what’s called a third epidemic of ROP as premature babies are getting smaller and smaller,” she said.
Whereas babies born weighing less than 1500 grams have a 50 to 70% risk of getting ROP, those under 750 grams have a 98% chance they will be affected in varying degrees, she said.
A small clinical study will now be conducted in collaboration with the Royal Children’s Hospital and Murdoch Children’s Research Institute.
The research could have far-reaching implications for improving eye disease in people with diabetic retinopathy.
“The same set of ideas are applicable,” Professor Wilkinson-Berka said. “An estimated 350 million people in the world today have diabetes and large numbers of these will have diabetic retinopathy.”
Research into animal models of diabetes will be conducted in the Central Clinical School and clinical studies in patients with diabetic retinopathy performed at the Royal Victorian Eye and Ear Hospital and Centre for Eye Research Australia (CERA) with Associate Professor Lyndell Lim and Dr Sanjeewa Wickremasinghe, beginning in October.
“My hopes are that this sort of immune system therapy can be given to patients safely. One of the treatments we’re investigating is a very safe thing to do. The therapies would not be a cure but would be added to current treatments to further improve them,” Professor Wilkinson-Berka said.
The research into diabetic retinopathy, previously supported by the Central Clinical School, has been bolstered by a grant of US $750,000 from the Juvenile Diabetes Research Foundation (JDRF). In addition, Dr Devy Deliyanti, first author of the paper, has recently been awarded a three-year JDRF Fellowship.
- Deliyanti D, Talia DM, Zhu T, Maxwell MJ, Agrotis A, Jerome JR, Hargreaves EM, Gerondakis S, Hibbs ML, Mackay F, Wilkinson-Berka JL. Foxp3+ Tregs are recruited to the retina to repair pathological angiogenesis. Nature Communications 10.1038/s41467-017-00751-w
- Jennifer Wilkinson-Berka laboratory: www.monash.edu/medicine/ccs/diabetes/research/wilkinson-berka-group